Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 5, 2024
Daily News
November 5, 2024
- Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
- Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
- Pricing Partially to Blame for Diabetes Drug Shortage: Society Chair
November 5, 2024
- AZ, Kyoto University to Study Pharmacovigilance Using RWD
November 5, 2024
- GRP Japan Acquires Hypoglycemia Drug Baqsimi from Lilly
November 5, 2024
- Meiji Seika Pharma “Preparing” to Sue CDP’s Haraguchi
November 5, 2024
- ROS1 Drug Effective in Japanese Subgroup: Nippon Kayaku
November 5, 2024
- Mitsubishi Tanabe Sales Up 6% on Radicava Oral Form
November 5, 2024
- PMDA Opens US Office in Washington, D.C.
November 5, 2024
- Santen’s Glaucoma Med Rhopressa Hits Shelves in South Korea
November 5, 2024
- Mitsubishi to Take Another Stab at Parkinson’s Drug Submission in US
November 5, 2024
- LEO Pharma, Kyowa Kirin to Wind Up Dovobet Collaboration
November 5, 2024
- FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…